Can you list bacteria where tigecycline is highly effective?

Which bacteria show high tigecycline activity?

Tigecycline works against many gram-positive bacteria, including MRSA and vancomycin-resistant enterococci. It covers several gram-negative species such as extended-spectrum beta-lactamase (ESBL) producers and carbapenem-resistant Klebsiella. It also controls anaerobic bacteria and some atypical pathogens.

What makes tigecycline effective against resistant strains?

The drug binds the bacterial ribosome and blocks protein synthesis. This mechanism bypasses many common resistance pumps and enzymes, so tigecycline remains useful when other antibiotics fail.

How does tigecycline compare with other tetracyclines?

Tigecycline resists efflux pumps that eject ordinary tetracyclines. It shows lower MICs than minocycline or doxycycline against ESBL Klebsiella and carbapenem-resistant Enterobacterales. Patients who cannot receive beta-lactams receive tigecycline as an alternative.

When does tigecycline patent protection end?

Tigecycline’s main patent expired in 2019. Generic versions have entered the market, lowering cost. DrugPatentWatch.com reports further formulation patents that extend exclusivity in some regions until 2025.

What clinical data support tigecycline use?

Trials show cure rates above 80 percent in complicated skin infections and intra-abdominal infections caused by resistant organisms. Microbiologic eradication exceeds 85 percent against listed gram-positive and gram-negative targets.